ifosfamide has been researched along with Mesothelioma in 21 studies
Mesothelioma: A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| ", ifosfamide (5 g/m (2) on day 1), carboplatin (300 mg/m (2) on day 1) and etoposide (150 mg/m (2) on days 2 and 3), administered every 4 weeks, to assess the treatment benefit for patients with malignant pleural mesothelioma." | 9.11 | [Evaluation of the therapeutic benefit of 41.8 degrees C whole body hyperthermia plus ifosfamide, carboplatin and etoposide (ICE) for patients with malignant pleural mesothelioma using the Modified Brunner-Score (MBS)]. ( Bakhshandeh, A; Bruns, I; Kohlmann, T; Wiedemann, GJ, 2004) |
| "Our aim was to determine the efficacy of ifosfamide, mesna, and interferon alpha combination therapy in malignant mesothelioma (MM) patients." | 9.11 | Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: results of a single center in central anatolia. ( Altinbas, M; Coskun, HS; Ekici, E; Er, O; Eser, B; Gulmez, I; Kaplan, B; Ozesmi, M; Ozkan, M, 2004) |
| " ifosfamide (5 g/m(2)), carboplatin (300 mg/m(2)) and etoposide (150 mg/m(2) on days 2 and 3), administered every 4 weeks, for patients with malignant pleural mesothelioma." | 9.10 | Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma. ( Bakhshandeh, A; Bruns, I; Dalhoff, K; Demedts, A; Eberhardt, K; Ehlers, EM; Gatzemeier, U; Gruber, Y; Hegewisch-Becker, S; Kaukel, E; Kohlmann, T; Koschel, G; Peters, SO; Robins, HI; Traynor, A; Wiedemann, GJ; Zumschlinge, R, 2003) |
| "The current study was conducted to assess the activity and toxicity of high-dose ifosfamide and mesna with recombinant human granulocyte-colony-stimulating factor (rhG-CSF), given in an outpatient setting, in the treatment of patients with unresectable malignant mesothelioma." | 9.10 | High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma. ( Antman, KH; Baker, LH; Balcerzak, SP; Bhoopalam, N; Chapman, RA; Middleman, EL; Rankin, C; Talbot, SM; Taub, RN, 2003) |
| "Thirty-one consecutive patients with histologically proven and symptomatic malignant mesothelioma were treated with two dose levels of ifosfamide." | 9.08 | Two dose levels of ifosfamide in malignant mesothelioma. ( Akbulut, H; Akyar, S; Cay, F; Demirkazik, A; Dinçol, D; Hastürk, S; Içli, F; Karaoğuz, H; Kurt, B, 1996) |
| "This study investigated the feasibility and efficacy of doxorubicin dose-escalated chemotherapy in combination with ifosfamide in patients with malignant mesothelioma." | 9.07 | A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. ( Corthouts, B; Dirix, LY; Prové, A; Schrijvers, D; van Marck, E; van Meerbeeck, J; van Oosterom, AT; Vermeire, P, 1994) |
| "Twenty-six patients with unresectable diffuse malignant mesothelioma were enrolled in Southwest Oncology Group (SWOG) study 8731 and treated with ifosfamide, 2 g/m2 intravenously for 4 days, and mesna 2 g/m2 intravenously for 5 days, every 3 weeks." | 9.07 | A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study. ( Balcerzak, SP; Berenberg, JL; Keppen, MD; Metch, B; Militello, L; Pierce, HI; Zidar, BL, 1992) |
| "Forty three patients with histologically confirmed malignant mesothelioma were entered onto an Eastern Cooperative Oncology Group phase II study of ifosfamide given with mesna." | 9.07 | An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. ( Borden, EC; Falkson, CI; Falkson, G; Hayes, JA; Hunt, M; Smith, TJ, 1992) |
| "From May 1988 to March 1990, 17 consecutive patients with histologically proven malignant mesothelioma were treated with epirubicin 75 mg/sqm i." | 9.07 | Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study. ( Bianchi, C; Foladore, S; Grandi, G; Magri, MD; Monfardini, S; Nicotra, M; Serra, C; Tommasi, M; Veronesi, A, 1992) |
| "Malignant mesothelioma is a rare malignancy with a median survival, ranging from 4 to 18 months in untreated patients." | 6.69 | Ifosfamide in malignant mesothelioma: a phase II study. ( Andersen, MK; Damgaard, K; Krarup-Hansen, A; Mårtensson, G; Olling, S; Thylen, A; Wallin, J; Winther-Nielsen, H, 1999) |
| ", ifosfamide (5 g/m (2) on day 1), carboplatin (300 mg/m (2) on day 1) and etoposide (150 mg/m (2) on days 2 and 3), administered every 4 weeks, to assess the treatment benefit for patients with malignant pleural mesothelioma." | 5.11 | [Evaluation of the therapeutic benefit of 41.8 degrees C whole body hyperthermia plus ifosfamide, carboplatin and etoposide (ICE) for patients with malignant pleural mesothelioma using the Modified Brunner-Score (MBS)]. ( Bakhshandeh, A; Bruns, I; Kohlmann, T; Wiedemann, GJ, 2004) |
| "Our aim was to determine the efficacy of ifosfamide, mesna, and interferon alpha combination therapy in malignant mesothelioma (MM) patients." | 5.11 | Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: results of a single center in central anatolia. ( Altinbas, M; Coskun, HS; Ekici, E; Er, O; Eser, B; Gulmez, I; Kaplan, B; Ozesmi, M; Ozkan, M, 2004) |
| " ifosfamide (5 g/m(2)), carboplatin (300 mg/m(2)) and etoposide (150 mg/m(2) on days 2 and 3), administered every 4 weeks, for patients with malignant pleural mesothelioma." | 5.10 | Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma. ( Bakhshandeh, A; Bruns, I; Dalhoff, K; Demedts, A; Eberhardt, K; Ehlers, EM; Gatzemeier, U; Gruber, Y; Hegewisch-Becker, S; Kaukel, E; Kohlmann, T; Koschel, G; Peters, SO; Robins, HI; Traynor, A; Wiedemann, GJ; Zumschlinge, R, 2003) |
| "The current study was conducted to assess the activity and toxicity of high-dose ifosfamide and mesna with recombinant human granulocyte-colony-stimulating factor (rhG-CSF), given in an outpatient setting, in the treatment of patients with unresectable malignant mesothelioma." | 5.10 | High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma. ( Antman, KH; Baker, LH; Balcerzak, SP; Bhoopalam, N; Chapman, RA; Middleman, EL; Rankin, C; Talbot, SM; Taub, RN, 2003) |
| "This study investigated the feasibility and efficacy of doxorubicin dose-escalated chemotherapy in combination with ifosfamide in patients with malignant mesothelioma." | 5.07 | A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. ( Corthouts, B; Dirix, LY; Prové, A; Schrijvers, D; van Marck, E; van Meerbeeck, J; van Oosterom, AT; Vermeire, P, 1994) |
| "Twenty-six patients with unresectable diffuse malignant mesothelioma were enrolled in Southwest Oncology Group (SWOG) study 8731 and treated with ifosfamide, 2 g/m2 intravenously for 4 days, and mesna 2 g/m2 intravenously for 5 days, every 3 weeks." | 5.07 | A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study. ( Balcerzak, SP; Berenberg, JL; Keppen, MD; Metch, B; Militello, L; Pierce, HI; Zidar, BL, 1992) |
| "Forty three patients with histologically confirmed malignant mesothelioma were entered onto an Eastern Cooperative Oncology Group phase II study of ifosfamide given with mesna." | 5.07 | An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. ( Borden, EC; Falkson, CI; Falkson, G; Hayes, JA; Hunt, M; Smith, TJ, 1992) |
| " The patient received ifosfamide (5 g/m2, day 1), carboplatin (300 mg/m2, day 1), etoposide (150 mg/m2, days 2-3) combined with WBH at 41." | 3.79 | [Chemotherapy in combination with whole-body hyperthermia in advanced malignant pleural mesothelioma]. ( Bakhshandeh, A; Bruns, I; Eberhardt, K; Wiedemann, GJ, 2000) |
| "Malignant mesothelioma is a rare malignancy with a median survival, ranging from 4 to 18 months in untreated patients." | 2.69 | Ifosfamide in malignant mesothelioma: a phase II study. ( Andersen, MK; Damgaard, K; Krarup-Hansen, A; Mårtensson, G; Olling, S; Thylen, A; Wallin, J; Winther-Nielsen, H, 1999) |
| "The ongoing phase I study reported here sought to determine the maximum tolerated doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin when given at specific times in combination with ifosfamide, mesna, and filgrastim." | 2.68 | Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results. ( Palackdharry, CS, 1997) |
| "Pediatr Blood Cancer 2015;62:274-278." | 1.40 | ( Adiguzel, R; Andreana, PR; Arslan, Z; Ates, M; Bemis, T; Bercovitch, LG; Bögli, S; Boucherez, J; Boudouf, S; Briat, JF; Brown, BM; Busemann, A; Buters, J; Byers, JS; Cairo, MS; Carrier, F; Chalmers, JJ; Chang, E; Chen, J; Chen, Y; Christenson, MK; Cielecka-Piontek, J; Cole, PA; Cooper, BS; Davis, PH; De Silva, RA; Decato, S; DeFries, RS; Demir, V; Denic, A; Deserno, M; Dickey, AM; Diss, E; Eberlein, B; Eyerich, S; Faluvegi, G; Farlow, MR; Fletcher, JW; Francetic, T; Furlan, L; Garbacki, P; Gartung, A; Garvin, JH; Gates, L; Gaymard, F; Ghetti, B; Gibson, MP; Griffin, RG; Hamed, M; Hammad, LA; Hammond, GB; Han, J; Hann, R; Hao, N; Harrison, LA; Heidecke, CD; Hutchins, GD; Inlow, M; Irmer, H; Jani, P; Jara-Cavieres, A; Jawadi, H; Jiang, Q; Jiang, Y; Kameda, T; Keeler, EG; Kim, H; Kim, R; Kim, S; Kinney, PL; Krause, A; Kumar, V; Kwok, Y; Lam, T; Lanni, F; Le May, M; Lee, A; Lee, JF; Lee, MJ; Leontyev, IV; Li, Q; Li, X; Liu, J; Liu, NK; Lominadze, D; Lösche, M; Lu, QB; Lu, Y; Lu, Z; Mach, H; Madsen, E; Marletta, M; Marlier, ME; McDonald, BC; McKay, IS; Mckenzie, CL; Mecozzi, S; Menges, P; Meyers, D; Michaelis, VK; Montooth, KL; Moore, LR; Morgan, JK; Morris, E; Movahed, M; Nalabothula, N; Narayanan, S; Nguyen, D; Nho, K; Oken, B; Ong, TC; Osborne, LS; Paczkowska, M; Park, EK; Pennino, D; Peters, S; Potluri, LP; Qin, C; Radhakrishnan, K; Randerson, JT; Rantanen, J; Reyt, G; Ring, J; Risacher, SL; Rodriguez, M; Saykin, AJ; Schmidt-Weber, CB; Sengelaub, DR; Shatters, RG; Shen, L; Shen, V; Shindell, DT; Stuchebrukhov, AA; Swaminathan, S; Takahashi, K; Talaczyńska, A; Tallman, EF; Tan, C; Terry, SF; Trabbic, KR; Trease, AJ; Tretter, C; Uitto, J; Váradi, A; von Bernstorff, W; Voulgarakis, A; Wagenhofer, M; Wahbeh, H; Wang, EN; Wang, X; Wells, RJ; West, JD; Williams, PS; Wolff, JE; Wootla, B; Xu, B; Xu, XM; Yoder, KK; Zalewski, P; Zan, GH; Zborowski, M; Zhang, HH; Zhang, W; Zhao, J; Zoecklein, L, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 12 (57.14) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 1 (4.76) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Almesned, R | 1 |
| Azzam, AZ | 1 |
| Aldeheshi, A | 1 |
| Amin, TM | 1 |
| Kameda, T | 1 |
| Takahashi, K | 1 |
| Kim, R | 1 |
| Jiang, Y | 1 |
| Movahed, M | 1 |
| Park, EK | 1 |
| Rantanen, J | 1 |
| Marlier, ME | 1 |
| DeFries, RS | 1 |
| Voulgarakis, A | 1 |
| Kinney, PL | 1 |
| Randerson, JT | 1 |
| Shindell, DT | 1 |
| Chen, Y | 1 |
| Faluvegi, G | 1 |
| Diss, E | 1 |
| Nalabothula, N | 1 |
| Nguyen, D | 1 |
| Chang, E | 1 |
| Kwok, Y | 1 |
| Carrier, F | 1 |
| Radhakrishnan, K | 1 |
| Lee, A | 1 |
| Harrison, LA | 1 |
| Morris, E | 1 |
| Shen, V | 1 |
| Gates, L | 1 |
| Wells, RJ | 1 |
| Wolff, JE | 1 |
| Garvin, JH | 1 |
| Cairo, MS | 1 |
| Eberlein, B | 1 |
| Hann, R | 1 |
| Eyerich, S | 1 |
| Pennino, D | 1 |
| Ring, J | 1 |
| Schmidt-Weber, CB | 1 |
| Buters, J | 1 |
| Dickey, AM | 1 |
| Trease, AJ | 1 |
| Jara-Cavieres, A | 1 |
| Kumar, V | 1 |
| Christenson, MK | 1 |
| Potluri, LP | 1 |
| Morgan, JK | 1 |
| Shatters, RG | 1 |
| Mckenzie, CL | 1 |
| Davis, PH | 1 |
| Osborne, LS | 1 |
| Francetic, T | 1 |
| Le May, M | 1 |
| Hamed, M | 1 |
| Mach, H | 1 |
| Meyers, D | 1 |
| Cole, PA | 1 |
| Chen, J | 1 |
| Li, Q | 1 |
| Zborowski, M | 1 |
| Moore, LR | 1 |
| Williams, PS | 1 |
| Chalmers, JJ | 1 |
| Cooper, BS | 1 |
| Hammad, LA | 1 |
| Montooth, KL | 1 |
| Bögli, S | 1 |
| Brown, BM | 1 |
| Marletta, M | 1 |
| Tretter, C | 1 |
| Wagenhofer, M | 1 |
| Leontyev, IV | 1 |
| Stuchebrukhov, AA | 1 |
| Ates, M | 1 |
| Demir, V | 1 |
| Adiguzel, R | 1 |
| Arslan, Z | 1 |
| Zan, GH | 1 |
| Tan, C | 1 |
| Deserno, M | 1 |
| Lanni, F | 1 |
| Lösche, M | 1 |
| Decato, S | 1 |
| Bemis, T | 1 |
| Madsen, E | 1 |
| Mecozzi, S | 1 |
| Trabbic, KR | 1 |
| De Silva, RA | 1 |
| Andreana, PR | 1 |
| Wahbeh, H | 1 |
| Oken, B | 1 |
| Uitto, J | 1 |
| Jiang, Q | 1 |
| Váradi, A | 1 |
| Bercovitch, LG | 1 |
| Terry, SF | 1 |
| Liu, J | 1 |
| Zhao, J | 1 |
| Lee, JF | 1 |
| Gartung, A | 1 |
| Jawadi, H | 1 |
| Zhang, W | 1 |
| Lominadze, D | 1 |
| Lee, MJ | 1 |
| Denic, A | 1 |
| Wootla, B | 1 |
| Zoecklein, L | 1 |
| Rodriguez, M | 1 |
| Kim, S | 1 |
| Nho, K | 1 |
| Risacher, SL | 1 |
| Inlow, M | 1 |
| Swaminathan, S | 1 |
| Yoder, KK | 1 |
| Shen, L | 1 |
| West, JD | 1 |
| McDonald, BC | 1 |
| Tallman, EF | 1 |
| Hutchins, GD | 1 |
| Fletcher, JW | 1 |
| Farlow, MR | 1 |
| Ghetti, B | 1 |
| Saykin, AJ | 1 |
| Reyt, G | 1 |
| Boudouf, S | 1 |
| Boucherez, J | 1 |
| Gaymard, F | 1 |
| Briat, JF | 1 |
| Hao, N | 1 |
| Zhang, HH | 1 |
| Gibson, MP | 1 |
| Jani, P | 1 |
| Wang, X | 1 |
| Lu, Y | 1 |
| Qin, C | 1 |
| Han, J | 1 |
| Lu, Z | 1 |
| Hammond, GB | 1 |
| Xu, B | 1 |
| Liu, NK | 1 |
| Byers, JS | 1 |
| Lam, T | 1 |
| Lu, QB | 1 |
| Sengelaub, DR | 1 |
| Xu, XM | 1 |
| von Bernstorff, W | 1 |
| Irmer, H | 1 |
| Menges, P | 1 |
| Peters, S | 1 |
| Heidecke, CD | 1 |
| Busemann, A | 1 |
| Li, X | 1 |
| Narayanan, S | 1 |
| Michaelis, VK | 1 |
| Ong, TC | 1 |
| Keeler, EG | 1 |
| Kim, H | 1 |
| McKay, IS | 1 |
| Griffin, RG | 1 |
| Wang, EN | 1 |
| Furlan, L | 1 |
| Paczkowska, M | 1 |
| Zalewski, P | 1 |
| Garbacki, P | 1 |
| Talaczyńska, A | 1 |
| Krause, A | 1 |
| Cielecka-Piontek, J | 1 |
| Bakhshandeh, A | 3 |
| Bruns, I | 3 |
| Traynor, A | 1 |
| Robins, HI | 1 |
| Eberhardt, K | 2 |
| Demedts, A | 1 |
| Kaukel, E | 1 |
| Koschel, G | 1 |
| Gatzemeier, U | 1 |
| Kohlmann, T | 2 |
| Dalhoff, K | 1 |
| Ehlers, EM | 1 |
| Gruber, Y | 1 |
| Zumschlinge, R | 1 |
| Hegewisch-Becker, S | 1 |
| Peters, SO | 1 |
| Wiedemann, GJ | 3 |
| Talbot, SM | 1 |
| Rankin, C | 1 |
| Taub, RN | 1 |
| Balcerzak, SP | 2 |
| Bhoopalam, N | 1 |
| Chapman, RA | 1 |
| Baker, LH | 1 |
| Middleman, EL | 1 |
| Antman, KH | 1 |
| Altinbas, M | 1 |
| Er, O | 1 |
| Ozkan, M | 1 |
| Coskun, HS | 1 |
| Gulmez, I | 1 |
| Ekici, E | 1 |
| Kaplan, B | 1 |
| Eser, B | 1 |
| Ozesmi, M | 1 |
| Dirix, LY | 1 |
| van Meerbeeck, J | 1 |
| Schrijvers, D | 1 |
| Corthouts, B | 1 |
| Prové, A | 1 |
| van Marck, E | 1 |
| Vermeire, P | 1 |
| van Oosterom, AT | 1 |
| Içli, F | 1 |
| Karaoğuz, H | 1 |
| Hastürk, S | 1 |
| Kurt, B | 1 |
| Akbulut, H | 1 |
| Dinçol, D | 1 |
| Demirkazik, A | 1 |
| Cay, F | 1 |
| Akyar, S | 1 |
| Krarup-Hansen, A | 2 |
| Palackdharry, CS | 1 |
| Gupta, NP | 1 |
| Agrawal, AK | 1 |
| Sood, S | 1 |
| Hemal, AK | 1 |
| Nair, M | 1 |
| Andersen, MK | 1 |
| Mårtensson, G | 1 |
| Winther-Nielsen, H | 1 |
| Thylen, A | 1 |
| Damgaard, K | 1 |
| Olling, S | 1 |
| Wallin, J | 1 |
| Smith, IE | 1 |
| Zidar, BL | 1 |
| Metch, B | 1 |
| Pierce, HI | 1 |
| Militello, L | 1 |
| Keppen, MD | 1 |
| Berenberg, JL | 1 |
| Falkson, G | 3 |
| Hunt, M | 1 |
| Borden, EC | 1 |
| Hayes, JA | 1 |
| Falkson, CI | 1 |
| Smith, TJ | 1 |
| Magri, MD | 1 |
| Foladore, S | 1 |
| Veronesi, A | 1 |
| Serra, C | 1 |
| Nicotra, M | 1 |
| Tommasi, M | 1 |
| Grandi, G | 1 |
| Monfardini, S | 1 |
| Bianchi, C | 1 |
| Pratt, CB | 1 |
| Meyer, WH | 1 |
| Jenkins, JJ | 1 |
| Avery, L | 1 |
| McKay, CP | 1 |
| Wyatt, RJ | 1 |
| Hancock, ML | 1 |
| Alberts, AS | 2 |
| van Zyl, L | 2 |
| Carmichael, J | 1 |
| Cantwell, BM | 1 |
| Harris, AL | 1 |
2 reviews available for ifosfamide and Mesothelioma
| Article | Year |
|---|---|
Malignant mesothelioma of the tunica vaginalis testis: a report of two cases and review of literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diagnosis, Differential; Drug Admin | 1999 |
[Chemotherapy in combination with whole-body hyperthermia in advanced malignant pleural mesothelioma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2000 |
13 trials available for ifosfamide and Mesothelioma
| Article | Year |
|---|---|
Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Dexame | 2003 |
High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Disease-Free Survival; Drug Thera | 2003 |
[Evaluation of the therapeutic benefit of 41.8 degrees C whole body hyperthermia plus ifosfamide, carboplatin and etoposide (ICE) for patients with malignant pleural mesothelioma using the Modified Brunner-Score (MBS)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Hyperthermia, Induce | 2004 |
Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: results of a single center in central anatolia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Humans; If | 2004 |
A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Feasibility Studies; Femal | 1994 |
Two dose levels of ifosfamide in malignant mesothelioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Drug Administratio | 1996 |
Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carci | 1997 |
Ifosfamide in malignant mesothelioma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Humans; Ifosfamide; Male; Mesothelioma; Middle Aged; | 1999 |
[Chemotherapy in combination with whole-body hyperthermia in advanced malignant pleural mesothelioma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2000 |
Carboplatin in small cell lung cancer: the Royal Marsden Hospital experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 1992 |
A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Male; Mesna | 1992 |
An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.
Topics: Drug Administration Schedule; Female; Humans; Ifosfamide; Infusions, Intravenous; Kidney Diseases; M | 1992 |
Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug | 1992 |
7 other studies available for ifosfamide and Mesothelioma
| Article | Year |
|---|---|
Bidirectional Intraoperative Chemotherapy Using Cisplatin and Ifosfamide for Intraperitoneal Mesothelioma in Severe Renal Impairment: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubicin; F | 2023 |
Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Arachidonic Acids; Asbestos; Asbestosis; Attitude | 2014 |
Studies concerning high dose ifosfamide to patients suffering from malignant mesothelioma.
Topics: Antineoplastic Agents, Alkylating; Humans; Ifosfamide; Mesothelioma | 1996 |
Ifosfamide, Fanconi's syndrome, and rickets.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Chronic Kidney Disease-Mineral an | 1991 |
Ifosfamide and mesna with doxorubicin have activity in malignant mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Ifosfamide; Mesna; Mesothelioma | 1990 |
A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluation; Female; H | 1989 |
Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna.
Topics: Adolescent; Adult; Aged; Drug Evaluation; Female; Humans; Ifosfamide; Kidney Diseases; Male; Mercapt | 1988 |